



24 July 2015  
EMA/38584/2015  
Press office

## Opinions on safety variations/PSURs

Adopted at the CHMP meeting of 20-23 July 2015

Name of medicine	INN	Scope
Aluvia	lopinavir / ritonavir	CHMP opinion to update the section 4.4 of the SmPC to indicate that strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure and thus related adverse events. Therefore, combination of bedaquiline with these medicines should be avoided.
Filgrastim Hexal and Zarzio	filgrastim	CHMP opinion to revise the wording related to the warning for latex-sensitive individuals in section 4.4 of the SmPC to indicate that the removable needle cap of the pre-filled syringe contains a derivative of natural rubber latex. Although no natural rubber latex has to date been detected in the removable needle cap, the use of filgrastim solution for injection in pre-filled syringe in latex-sensitive individuals has not been studied and thus there is a potential risk for hypersensitivity reactions that cannot be completely ruled out.



Name of medicine	INN	Scope
Mekinist	trametinib	CHMP opinion to update sections 4.4 and 4.8 of the SmPC to add warnings regarding deep vein thrombosis (DVT) and pulmonary embolism (PE) and to update the safety information on haemorrhage.
Vfend	voriconazole	CHMP opinion to update the section 4.4 of the SmPC with the information that higher frequency of liver enzyme elevations was observed in the paediatric population.
Xeplion/ Paliperidone Janssen	paliperidone	CHMP opinion to update sections 4.4 and 4.8 of the SmPC to add a warning and update the safety information collected during postmarketing experience on occurrence of hypersensitivity reactions in patients who have previously tolerated oral risperidone or paliperidone.
Betmiga	mirabegron	PSUR assessment resulting in a variation to update section 4.3 of the SmPC to add a new contraindication in patients with uncontrolled hypertension. In addition, update of section 4.4 of the SmPC to amend the existing warning on hypertension to reflect the recommendation to measure the blood pressure. In addition, update of section 4.8 of the SmPC to add urinary retention and insomnia.
Evoltra	clofarabine	PSUR assessment resulting in a variation to update of section 4.4 of the SmPC to add a warning on discontinuation of clofarabine if substantial increase in liver enzymes is observed. In addition, update of section 4.8 of the SmPC to add the adverse reaction "hepatic failure", with a frequency "common".
Iclusig	ponatinib	PSUR assessment resulting in an update of sections 4.4 and 4.8 of the SmPC to update the warnings on vascular occlusion, hypertension and hepatotoxicity and to add the adverse reactions hypertensive crisis and hepatic failure with a frequency "uncommon".
Perjeta	pertuzumab	PSUR assessment resulting in a variation to update of section 4.4 of the SmPC to add a warning on severe diarrhoea.
Visudyne	Verteporfin	PSUR assessment resulting in an update of section 4.4 and 4.8 of the SmPC to add "convulsions" to the symptoms potentially associated with vasovagal and hypersensitivity reactions.